<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924429</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-1186</org_study_id>
    <nct_id>NCT01924429</nct_id>
  </id_info>
  <brief_title>Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation</brief_title>
  <official_title>Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Newcorn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Vyvanse, an FDA approved medication
      used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), on brain activity
      in adults with attention-deficit hyperactivity disorder (ADHD). Participants may qualify for
      participation in this study because they have ADHD and are willing to participate in two
      Functional Magnetic Resonance Imaging (fMRI) scans and receive Vyvanse for treatment of their
      symptoms. Another purpose of this study is to collect and bank samples of blood for research
      to examine how genes influence brain activation seen during the brain scans. The study also
      seeks to find out whether certain genes are related to ADHD. Participants' entire genetic
      makeup will not be determined from this sample.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Go/No-Go Task Percentage Assessed by fMRI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Performance Measures on the Go/No-Go Task assessed by fMRI as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder. The Go/No-Go Task is a neuropsychological test that provides a direct measure of number of responses made that are &quot;correct&quot; or &quot;incorrect&quot;. It is not a scale. Reported are the percentage of correct responses on that direct performance measure. 0% correct is worse than 100% correct.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI Reaction Time</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Reaction-time, as measured by the reaction time test Go/No-Go Task as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BRIEF-A</measure>
    <time_frame>Baseline</time_frame>
    <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (0 to 100, with 50 +/-1 SD = 'Normal', higher is worse, more impaired)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRIEF-A</measure>
    <time_frame>at one week</time_frame>
    <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRIEF-A</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASRS - Expanded</measure>
    <time_frame>Baseline</time_frame>
    <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASRS - Expanded</measure>
    <time_frame>at one week</time_frame>
    <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASRS - Expanded</measure>
    <time_frame>at 4 weeks</time_frame>
    <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WRAADS</measure>
    <time_frame>Baseline</time_frame>
    <description>The Wender-Reimherr adult attention deficit disorder scale (WRAADS): Symptom measure for emotional functioning/lability, generally reported as Sum of Responses (0-2 per item, higher = more impaired).
For this outcome measure, Average scores for particular questions were taken - specifically question 3, question 4, and question 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADHD-RS-IV Combined Sum</measure>
    <time_frame>Baseline</time_frame>
    <description>ADHD symptoms and severity. Norm referenced interview to assess severity and frequency of ADHD symptoms. 18 Items are scored 0-3 to reflect severity and frequency of ADHD symptoms, and a sum is taken. Full range from 0 to 54, with higher number indicating more symptoms and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADHD-Inattentive</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>ADHD symptoms and severity - subscale for Inattentiveness. 9-item scale, each scored 0-3, with total from 0 to 27. Higher score indicates higher level of inattentiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical Global Impressions - CGI-I: Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>baseline</time_frame>
    <description>CGI-S: Severity of impairment due to ADHD was measured by the Clinical Global Impressions-Severity scale (CGI-S). Lower scores indicate less severe impairment from symptoms, with a CGI-I=1 indicating the person is &quot;normal&quot; with no impairment. (1= normal, not ill, 2= minimally ill, 3= mildly ill, 4= moderately ill, 5=markedly ill, 6=severely ill, 7= very severely ill)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>On Drug then off Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off drug then on drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine</intervention_name>
    <description>Escalating stepped dose titration: 30, 50 or 70mg</description>
    <arm_group_label>Off drug then on drug</arm_group_label>
    <arm_group_label>On Drug then off Drug</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary DSM-IV-TR diagnosis of adult ADHD (inattentive, hyperactive-impulsive or
             combined subtype), established via the ACDS v1.2.

          -  Must be between 18-55 years, inclusive.

          -  Provides written informed consent.

        Exclusion Criteria:

          -  Lifetime or current diagnosis of bipolar disorder, schizophrenia or schizoaffective
             disorder.

          -  Current diagnosis of comorbid major depressive disorder, anxiety disorder or dysthymia
             or any controlled (i.e. requires pharmacological treatment) comorbid diagnosis.
             Participants with uncontrolled depressive or anxiety disorders may participate if, in
             the opinion of the Principal Investigator, the disorder will not confound the results
             of efficacy or safety assessments, increase risk to the participant or lead to
             difficulty complying with the protocol.

          -  Meets current DSM-IV-TR criteria for alcohol or any non-alcohol substance abuse or
             dependence disorder.

          -  Have organic brain disease (such as dementia) or traumatic brain injury residua. Have
             a history of seizure disorder (other than febrile seizures) or participants who have
             taken (or are currently taking) anticonvulsants for seizure control.

          -  Females who are currently pregnant or breast feeding, and women of child-bearing
             potential who are not currently using an adequate form of birth control.

          -  Participants with clinically significant abnormalities in ECG results that are deemed
             exclusionary in the opinion of the Principal Investigator will not be allowed in the
             trial.

          -  Participants who work the night shift or another schedule that would preclude
             beginning the daily dose of study medication in the morning.

          -  Participants with a positive urine drug result at Screening.

          -  Medical conditions limiting participation in the study.

          -  Documented history of intolerance or non-responsivity to methylphenidate or
             amphetamines.

          -  Have a medical condition that would, in the opinion of the study physician, make
             participation medically hazardous.

          -  ADHD, Not Otherwise Specified

          -  History of surgery involving metal implants, metal fragments in the eyes, braces, or a
             pacemaker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Newcorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jeffrey Newcorn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>ADHD</keyword>
  <keyword>fMRI</keyword>
  <keyword>Imaging</keyword>
  <keyword>Vyvanse</keyword>
  <keyword>Stimulant Medication</keyword>
  <keyword>Treatment</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Adult</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>On Drug Then Off Drug</title>
          <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
        </group>
        <group group_id="P2">
          <title>Off Drug Then on Drug</title>
          <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - First Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Second Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>On Drug, Then Off Drug</title>
          <description>fMRI #1 on drug, #2 off drug</description>
        </group>
        <group group_id="B2">
          <title>Off Drug, Then on Drug</title>
          <description>fMRI #1 off drug, #2 on drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.46" spread="11.82"/>
                    <measurement group_id="B2" value="37.27" spread="11.81"/>
                    <measurement group_id="B3" value="35.84" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Go/No-Go Task Percentage Assessed by fMRI</title>
        <description>Performance Measures on the Go/No-Go Task assessed by fMRI as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder. The Go/No-Go Task is a neuropsychological test that provides a direct measure of number of responses made that are &quot;correct&quot; or &quot;incorrect&quot;. It is not a scale. Reported are the percentage of correct responses on that direct performance measure. 0% correct is worse than 100% correct.</description>
        <time_frame>8 weeks</time_frame>
        <population>Performance measures are done while participants are off drug and while on drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received fMRI while off drug</description>
          </group>
          <group group_id="O2">
            <title>Lisdexamfetamine</title>
            <description>Participants received fMRI while on drug</description>
          </group>
        </group_list>
        <measure>
          <title>The Go/No-Go Task Percentage Assessed by fMRI</title>
          <description>Performance Measures on the Go/No-Go Task assessed by fMRI as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder. The Go/No-Go Task is a neuropsychological test that provides a direct measure of number of responses made that are &quot;correct&quot; or &quot;incorrect&quot;. It is not a scale. Reported are the percentage of correct responses on that direct performance measure. 0% correct is worse than 100% correct.</description>
          <population>Performance measures are done while participants are off drug and while on drug.</population>
          <units>percentage correct responses/inhibitions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Happy Correct Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" spread="2.8"/>
                    <measurement group_id="O2" value="97.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Happy Correct Inhibitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" spread="9.4"/>
                    <measurement group_id="O2" value="87.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sad Correct Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" spread="7.7"/>
                    <measurement group_id="O2" value="88.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sad Correct Inhibitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" spread="12.5"/>
                    <measurement group_id="O2" value="86.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral Correct Responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" spread="12.2"/>
                    <measurement group_id="O2" value="95.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral Correct Inhibitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="12.3"/>
                    <measurement group_id="O2" value="79.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>fMRI Reaction Time</title>
        <description>Reaction-time, as measured by the reaction time test Go/No-Go Task as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder</description>
        <time_frame>up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received fMRI while off drug</description>
          </group>
          <group group_id="O2">
            <title>Lisdexamfetamine</title>
            <description>Participants received fMRI while on drug</description>
          </group>
        </group_list>
        <measure>
          <title>fMRI Reaction Time</title>
          <description>Reaction-time, as measured by the reaction time test Go/No-Go Task as a Function of Trial Type, Face Emotion, and Drug Condition in Adults with Attention-Deficit/Hyperactivity Disorder</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Happy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532" spread="99"/>
                    <measurement group_id="O2" value="519" spread="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533" spread="110"/>
                    <measurement group_id="O2" value="509" spread="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553" spread="109"/>
                    <measurement group_id="O2" value="533" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BRIEF-A</title>
        <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (0 to 100, with 50 +/-1 SD = 'Normal', higher is worse, more impaired)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>BRIEF-A</title>
          <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (0 to 100, with 50 +/-1 SD = 'Normal', higher is worse, more impaired)</description>
          <units>t-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.64" spread="11.89"/>
                    <measurement group_id="O2" value="73.5" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BRIEF-A</title>
        <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
        <time_frame>at one week</time_frame>
        <population>not collected</population>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>BRIEF-A</title>
          <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
          <population>not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BRIEF-A</title>
        <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
        <time_frame>at 4 weeks</time_frame>
        <population>not collected</population>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>BRIEF-A</title>
          <description>Behavior Rating Inventory of Executive Function®-Adult Version (BRIEF-A): Norm Referenced Measure of Impaired Executive Functioning, reported in T-Scores (higher is worse)</description>
          <population>not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ASRS - Expanded</title>
        <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>ASRS - Expanded</title>
          <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" spread="25.59"/>
                    <measurement group_id="O2" value="86" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ASRS - Expanded</title>
        <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
        <time_frame>at one week</time_frame>
        <population>not collected</population>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>ASRS - Expanded</title>
          <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
          <population>not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ASRS - Expanded</title>
        <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
        <time_frame>at 4 weeks</time_frame>
        <population>not collected</population>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>ASRS - Expanded</title>
          <description>ADHD and Related Symptoms Measure (ASRS): self report, reported as Sum of Responses (0-4 per item, higher = more impaired) 0-26 (normal range) and &gt;27 (clinically significant symptoms).</description>
          <population>not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WRAADS</title>
        <description>The Wender-Reimherr adult attention deficit disorder scale (WRAADS): Symptom measure for emotional functioning/lability, generally reported as Sum of Responses (0-2 per item, higher = more impaired).
For this outcome measure, Average scores for particular questions were taken - specifically question 3, question 4, and question 5.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>WRAADS</title>
          <description>The Wender-Reimherr adult attention deficit disorder scale (WRAADS): Symptom measure for emotional functioning/lability, generally reported as Sum of Responses (0-2 per item, higher = more impaired).
For this outcome measure, Average scores for particular questions were taken - specifically question 3, question 4, and question 5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.86"/>
                    <measurement group_id="O2" value="0.94" spread="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.22"/>
                    <measurement group_id="O2" value="1.47" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.35"/>
                    <measurement group_id="O2" value="1.82" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADHD-RS-IV Combined Sum</title>
        <description>ADHD symptoms and severity. Norm referenced interview to assess severity and frequency of ADHD symptoms. 18 Items are scored 0-3 to reflect severity and frequency of ADHD symptoms, and a sum is taken. Full range from 0 to 54, with higher number indicating more symptoms and severity.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD-RS-IV Combined Sum</title>
          <description>ADHD symptoms and severity. Norm referenced interview to assess severity and frequency of ADHD symptoms. 18 Items are scored 0-3 to reflect severity and frequency of ADHD symptoms, and a sum is taken. Full range from 0 to 54, with higher number indicating more symptoms and severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="6.98"/>
                    <measurement group_id="O2" value="13.67" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.65" spread="8.53"/>
                    <measurement group_id="O2" value="31.00" spread="14.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADHD-Inattentive</title>
        <description>ADHD symptoms and severity - subscale for Inattentiveness. 9-item scale, each scored 0-3, with total from 0 to 27. Higher score indicates higher level of inattentiveness.</description>
        <time_frame>4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD-Inattentive</title>
          <description>ADHD symptoms and severity - subscale for Inattentiveness. 9-item scale, each scored 0-3, with total from 0 to 27. Higher score indicates higher level of inattentiveness.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="4.53"/>
                    <measurement group_id="O2" value="8.83" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.94" spread="6.21"/>
                    <measurement group_id="O2" value="19.2" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-I</title>
        <description>Clinical Global Impressions - CGI-I: Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-I</title>
          <description>Clinical Global Impressions - CGI-I: Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="1.13"/>
                    <measurement group_id="O2" value="2.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-S</title>
        <description>CGI-S: Severity of impairment due to ADHD was measured by the Clinical Global Impressions-Severity scale (CGI-S). Lower scores indicate less severe impairment from symptoms, with a CGI-I=1 indicating the person is &quot;normal&quot; with no impairment. (1= normal, not ill, 2= minimally ill, 3= mildly ill, 4= moderately ill, 5=markedly ill, 6=severely ill, 7= very severely ill)</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>On Drug Then Off Drug</title>
            <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
          <group group_id="O2">
            <title>Off Drug Then on Drug</title>
            <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-S</title>
          <description>CGI-S: Severity of impairment due to ADHD was measured by the Clinical Global Impressions-Severity scale (CGI-S). Lower scores indicate less severe impairment from symptoms, with a CGI-I=1 indicating the person is &quot;normal&quot; with no impairment. (1= normal, not ill, 2= minimally ill, 3= mildly ill, 4= moderately ill, 5=markedly ill, 6=severely ill, 7= very severely ill)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.0"/>
                    <measurement group_id="O2" value="4.95" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>On Drug, Then Off Drug</title>
          <description>Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
        </group>
        <group group_id="E2">
          <title>Off Drug, Then on Drug</title>
          <description>Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
Lisdexamphetamine: Escalating stepped dose titration: 30, 50 or 70mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Incidental finding on brain scan</sub_title>
                <description>benign</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Incidental Physical finding</sub_title>
                <description>benign</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Heart Racing</sub_title>
                <description>secondary to anxiety</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>feeling agitated</sub_title>
                <description>counseled to reduce caffeine</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anxious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Restless</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Seasonal allergies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Subjectively feeling &quot;stuck&quot;</sub_title>
                <description>no motivation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Suspiciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Reduced Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Sores</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Newcorn</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-8775</phone>
      <email>Jeffrey.newcorn@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

